

Nathan A Pennell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3093418/publications.pdf>

Version: 2024-02-01

156
papers

16,748
citations

81743

39
h-index

17055

122
g-index

163
all docs

163
docs citations

163
times ranked

28410
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive molecular profiling of lung adenocarcinoma. <i>Nature</i> , 2014, 511, 543-550.	13.7	4,572
2	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020, 578, 82-93.	13.7	1,966
3	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
4	Reactive microgliosis. <i>Progress in Neurobiology</i> , 1999, 57, 563-581.	2.8	1,074
5	Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008, 14, 822-827.	15.2	1,015
6	Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	13.9	505
7	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	7.7	422
8	Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4417-4424.	0.8	405
9	Incidence of Pneumonitis With Use of Programmed–Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer. <i>Chest</i> , 2017, 152, 271-281.	0.4	381
10	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	0.8	318
11	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 230-241.	2.3	284
12	Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i>KRAS</i> ^{G12C} Mutation. <i>New England Journal of Medicine</i> , 2022, 387, 120-131.	13.9	269
13	Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 531-542.	1.8	210
14	A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. <i>Thyroid</i> , 2008, 18, 317-323.	2.4	185
15	Time to initial cancer treatment in the United States and association with survival over time: An observational study. <i>PLoS ONE</i> , 2019, 14, e0213209.	1.1	179
16	Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). <i>Journal of Thoracic Oncology</i> , 2018, 13, 1393-1399.	0.5	169
17	Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , 1998, 86, 1-12.	1.1	160
18	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	0.8	159

#	ARTICLE	IF	CITATIONS
19	Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1771-1775.	0.5	157
20	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
21	A genetic basis for the variation in the vulnerability of cancer to DNA damage. <i>Nature Communications</i> , 2016, 7, 11428.	5.8	136
22	Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. <i>Blood Advances</i> , 2020, 4, 5966-5975.	2.5	124
23	ALK Status Testing in Non-Small Cell Lung Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 341-346.	1.2	115
24	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1547-1552.	3.3	115
25	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
26	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	0.8	101
27	Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, S3-S10.	0.8	96
28	Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC. <i>Oncologist</i> , 2009, 14, 399-411.	1.9	86
29	Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	81
30	Prospective Clinical Study of Precision Oncology in Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	70
31	ALK Status Testing in Non-Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material. <i>Journal of Thoracic Oncology</i> , 2014, 9, 464-468.	0.5	57
32	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	57
33	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	0.8	54
34	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2018, 19, e335-e348.	1.1	53
35	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. <i>Journal of Clinical Oncology</i> , 2019, 37, 2360-2367.	0.8	52
36	XL647: A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, 219-226.	0.5	51

#	ARTICLE	IF	CITATIONS
37	Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. <i>PLoS ONE</i> , 2018, 13, e0197743.	1.1	50
38	<i>MET</i> Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. <i>JCO Precision Oncology</i> , 2021, 5, 653-663.	1.5	50
39	EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 86, 158-163.	0.9	47
40	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
41	RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1714-1719.	0.5	40
42	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187.	0.9	40
43	Risk of thromboembolism in patients with ALK and EGFR mutant lung cancer: A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 822-829.	1.9	37
44	Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. <i>Investigational New Drugs</i> , 2014, 32, 362-368.	1.2	36
45	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. <i>Journal of Thoracic Disease</i> , 2018, 10, 3909-3921.	0.6	35
46	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. <i>Journal of Clinical Oncology</i> , 2014, 32, 7514-7514.	0.8	35
47	Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer. <i>Practical Radiation Oncology</i> , 2013, 3, 301-306.	1.1	33
48	Impact of the COVID-19 Pandemic on Healthcare Workers' Risk of Infection and Outcomes in a Large, Integrated Health System. <i>Journal of General Internal Medicine</i> , 2020, 35, 3293-3301.	1.3	33
49	Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model. <i>Journal of Clinical Oncology</i> , 2018, 36, 9031-9031.	0.8	33
50	Colonization of Neural Allografts by Host Microglial Cells: Relationship to Graft Neovascularization. <i>Cell Transplantation</i> , 1997, 6, 221-230.	1.2	31
51	Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine. <i>Seminars in Hematology</i> , 2017, 54, 198-204.	1.8	29
52	High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 646-653.	0.5	28
53	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
54	Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. <i>Oncologist</i> , 2020, 25, 562-e1012.	1.9	26

#	ARTICLE	IF	CITATIONS
55	Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. , 2022, 10, e003778.		26
56	Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treatment and Research Communications, 2019, 19, 100126.	0.7	24
57	The CoVIDâ€™E risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDâ€™19. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	1.9	23
58	The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator. JCO Oncology Practice, 2022, 18, 578-583.	1.4	23
59	Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1156-1162.	0.5	22
60	Impact of EGFR mutation and ALK rearrangement on the outcomes of nonâ€™small cell lung cancer patients with brain metastasis. Neuro-Oncology, 2020, 22, 267-277.	0.6	22
61	Lectin staining of sheep microglia. Histochemistry, 1994, 102, 483-486.	1.9	21
62	Characterization of Myomodulin-Related Peptides From the Pulmonate Snail Helix aspersa. Peptides, 1997, 18, 1099-1106.	1.2	21
63	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21.	0.9	21
64	Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of â€™1% by the USA Food and Drug Administration. Annals of Oncology, 2019, 30, 1686-1688.	0.6	20
65	Identifying delays in care for patients with NSCLC using value-stream mapping.. Journal of Clinical Oncology, 2018, 36, 136-136.	0.8	20
66	Colonization of neural allografts by host microglial cells: Relationship to graft neovascularization. Cell Transplantation, 1997, 6, 221-230.	1.2	19
67	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. Oncologist, 2015, 20, 1298-1303.	1.9	19
68	Interns' Work Hours. New England Journal of Medicine, 2005, 352, 726-728.	13.9	18
69	Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. European Journal of Cancer, 2021, 148, 146-158.	1.3	18
70	Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 8504-8504.	0.8	18
71	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 144-154.	1.8	17
72	Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. The Lancet Healthy Longevity, 2022, 3, e143-e152.	2.0	16

#	ARTICLE	IF	CITATIONS
73	Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2011, 12, 350-359.	1.1	15
74	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. <i>Nature Communications</i> , 2019, 10, 5143.	5.8	15
75	Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. <i>Scientific Reports</i> , 2021, 11, 18174.	1.6	15
76	Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. <i>Cancer</i> , 2020, 126, 1060-1067.	2.0	13
77	Tracing of fluoro-gold pre-labeled microglia injected into the adult rat brain. , 1998, 23, 84-88.		12
78	Biofeedback Assisted Stress Management in Patients with Lung Cancer: A Feasibility Study. <i>Applied Psychophysiology Biofeedback</i> , 2015, 40, 201-208.	1.0	12
79	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	0.9	11
80	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). <i>Annals of Oncology</i> , 2020, 31, S1202-S1203.	0.6	11
81	Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 3071-3078.	1.3	11
82	Patterns of Recurrence and Overall Survival in Incidental Lung Cancer in Explanted Lungs. <i>Annals of Thoracic Surgery</i> , 2019, 107, 891-896.	0.7	10
83	A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with nonsquamous non-small cell lung cancer (NSCLC) in the United States.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9529-9529.	0.8	10
84	Selection of chemotherapy for patients with advanced non-small cell lung cancer. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S46-S50.	0.6	10
85	The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 369-372.	0.6	9
86	Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes. <i>Oncologist</i> , 2020, 25, 921-924.	1.9	9
87	Increase in time to initiating cancer therapy and association with worsened survival in curative settings: A U.S. analysis of common solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6557-6557.	0.8	9
88	mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 144-154.	1.8	9
89	Lung cancer treatment outcomes in recipients of lung transplant. <i>Translational Lung Cancer Research</i> , 2015, 4, 784-91.	1.3	9
90	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9

#	ARTICLE	IF	CITATIONS
91	Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. <i>Scientific Reports</i> , 2021, 11, 7490.	1.6	8
92	EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data. <i>Translational Lung Cancer Research</i> , 2013, 2, 251-5.	1.3	8
93	The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. <i>Clinical Lung Cancer</i> , 2022, 23, 108-115.	1.1	8
94	Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor Use for Patients With Non-Small-Cell Lung Cancer Who Receive Chemotherapy: An ASCO Quality Training Program Project of the Cleveland Clinic Taussig Cancer Institute. <i>Journal of Oncology Practice</i> , 2016, 12, e101-e107.	2.5	7
95	Best Practices in Treatment Selection for Patients with Advanced NSCLC. <i>Cancer Control</i> , 2016, 23, 2-14.	0.7	7
96	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. <i>Oncologist</i> , 2019, 24, 4-8.	1.9	7
97	A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8595-TPS8595.	0.8	7
98	Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	6
99	Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11603-11603.	0.8	6
100	Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges. <i>Annals of Translational Medicine</i> , 2017, 5, 378-378.	0.7	6
101	Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 4410-4424.	3.2	6
102	Investigational agents in the management of non-small cell lung cancer. <i>Current Oncology Reports</i> , 2009, 11, 275-284.	1.8	5
103	PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 569.	3.4	5
104	My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now? Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 696-707.	1.8	5
105	Hereditary implications of somatic tumor testing.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1523-1523.	0.8	5
106	Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11547-11547.	0.8	5
107	The Morbidity and Mortality Conference (MMC) in Oncology: A patient safety and root cause analysis (RCA)-driven approach at the Cleveland Clinic Taussig Cancer Institute (TCI).. <i>Journal of Clinical Oncology</i> , 2014, 32, 191-191.	0.8	5
108	Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer. <i>Journal of Thoracic Oncology</i> , 2022, 17, 179-181.	0.5	5

#	ARTICLE	IF	CITATIONS
109	Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?. Current Treatment Options in Oncology, 2012, 13, 478-490.	1.3	4
110	High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. Lung Cancer, 2018, 126, 48-54.	0.9	4
111	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist, 2021, 26, 523-532.	1.9	4
112	Prospective clinical study of precision oncology in solid tumors.. Journal of Clinical Oncology, 2015, 33, 6585-6585.	0.8	4
113	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9079-9079.	0.8	4
114	Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. Oncologist, 2022, 27, 407-413.	1.9	4
115	Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib. Journal of Thoracic Oncology, 2012, 7, 1200-1201.	0.5	3
116	Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study. Blood, 2019, 134, 3651-3651.	0.6	3
117	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. Blood, 2020, 136, 56-58.	0.6	3
118	Evaluation of radiomic features on baseline CT scan to predict clinical benefit for pemetrexed based chemotherapy in metastatic lung adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 11582-11582.	0.8	3
119	Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials.. Journal of Clinical Oncology, 2017, 35, e20647-e20647.	0.8	3
120	A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, TPS2598-TPS2598.	0.8	3
121	Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. Biomarkers in Medicine, 2007, 1, 203-207.	0.6	2
122	Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).. Journal of Clinical Oncology, 2015, 33, 6609-6609.	0.8	2
123	Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.. Journal of Clinical Oncology, 2016, 34, 9059-9059.	0.8	2
124	Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. Reviews on Recent Clinical Trials, 2017, 12, 51-58.	0.4	2
125	Treating acquired resistance to EGFR-tyrosine kinase inhibitors: still a work in progress. Translational Lung Cancer Research, 2012, 1, 149-51.	1.3	2
126	Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub. Blood, 2020, 136, 7-8.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3353-3356.	0.8	2
128	Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer. <i>Clinical Lung Cancer</i> , 2011, 12, 94-99.	1.1	1
129	Treating Anaplastic Lymphoma Kinase-Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of Crizotinib. <i>Journal of Oncology Practice</i> , 2012, 8, 34s-37s.	2.5	1
130	Fast-Growing Plasmacytoma. <i>American Journal of the Medical Sciences</i> , 2016, 351, 308.	0.4	1
131	Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening. <i>Oncologist</i> , 2020, 25, 364-365.	1.9	1
132	Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6565-6565.	0.8	1
133	Phase II study of stereotactic radiosurgery or other local ablation followed by erlotinib for patients with EGFR mutation who have previously progressed on an EGFR tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2017, 35, e20623-e20623.	0.8	1
134	Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?. <i>Journal of Thoracic Disease</i> , 2020, 12, 5042-5045.	0.6	1
135	Patients as real time teachers. <i>Journal of Cancer Education</i> , 2007, 22, 131-133.	0.6	0
136	Phase I/II Trial of the Addition of Erlotinib to Pre- and Postoperative Chemotherapy/Hyperfractionated Radiotherapy, and as Maintenance, for Resectable Mediastinoscopy-defined Stage III Non-small-cell Lung Cancer (NSCLC): Report on the Phase II Component. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, S58.	0.4	0
137	Superior vena cava syndrome in lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 309-315.	1.5	0
138	New Guideline Sets the Ground Rules for Routine Molecular Testing in Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 413-414.	1.2	0
139	Adjuvant Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer. <i>Chest</i> , 2016, 149, 1357-1359.	0.4	0
140	P2.03a-040 Safety and Efficacy of Nab-Paclitaxel for 2nd Line Treatment of Elderly Patients with Stage IV Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S912-S913.	0.5	0
141	An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 457.	1.9	0
142	Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor-Mutant Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 679.	3.4	0
143	Circulating tumor cells enrichment and characterization in ALK-translocation positive lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19025-e19025.	0.8	0
144	Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC): A Cleveland Clinic (CC) experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12515-e12515.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Patient-centered outcomes with post-approval nivolumab in metastatic NSCLC at the Cleveland Clinic Taussig Cancer Institute (TCI).. Journal of Clinical Oncology, 2016, 34, 29-29.	0.8	0
146	Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer.. Journal of Clinical Oncology, 2016, 34, e14073-e14073.	0.8	0
147	Preoperative neutrophil lymphocyte ratio as a predictor of outcomes in patients with early stage non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e23069-e23069.	0.8	0
148	The effect of routine early palliative care (PC) consultation on aggressiveness of care at the end of life (EOL) in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e21688-e21688.	0.8	0
149	Precision oncology experience at a tertiary care center.. Journal of Clinical Oncology, 2017, 35, e18118-e18118.	0.8	0
150	Association of delays in time to surgery for resectable stage IIIA non-small cell lung cancer with survival.. Journal of Clinical Oncology, 2017, 35, e20056-e20056.	0.8	0
151	PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non-small-cell lung cancer (ES-NSCLC).. Journal of Clinical Oncology, 2018, 36, 12059-12059.	0.8	0
152	Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic.. Journal of Clinical Oncology, 2018, 36, e18710-e18710.	0.8	0
153	ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. Translational Lung Cancer Research, 2013, 2, E1-3.	1.3	0
154	Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors. Blood, 2021, 138, 3223-3223.	0.6	0
155	Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic. Blood, 2020, 136, 41-42.	0.6	0
156	Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng <i>et al</i> ., 2022, 10, e005086.		0